Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases
A Wasilewska, M Winiarska, M Olszewska… - … in Dermatology and …, 2016 - termedia.pl
A Wasilewska, M Winiarska, M Olszewska, L Rudnicka
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 2016•termedia.plPsoriasis is a chronic skin disease caused by the excessive secretion of inflammatory
cytokines. Available therapeutic options include biologic drugs such as tumor necrosis factor
alpha inhibitors and interleukin 12/23 (IL-12/23) inhibitors. The recent discovery of IL-17,
which contributes to development of psoriasis, opened new possibilities for further treatment
modalities. Currently, one anti-IL17 biological agent is approved for the treatment–a fully
human monoclonal antibody that targets IL-17A (secukinumab). Further clinical trials …
cytokines. Available therapeutic options include biologic drugs such as tumor necrosis factor
alpha inhibitors and interleukin 12/23 (IL-12/23) inhibitors. The recent discovery of IL-17,
which contributes to development of psoriasis, opened new possibilities for further treatment
modalities. Currently, one anti-IL17 biological agent is approved for the treatment–a fully
human monoclonal antibody that targets IL-17A (secukinumab). Further clinical trials …
Abstract
Psoriasis is a chronic skin disease caused by the excessive secretion of inflammatory cytokines. Available therapeutic options include biologic drugs such as tumor necrosis factor alpha inhibitors and interleukin 12/23 (IL-12/23) inhibitors. The recent discovery of IL-17, which contributes to development of psoriasis, opened new possibilities for further treatment modalities. Currently, one anti-IL17 biological agent is approved for the treatment–a fully human monoclonal antibody that targets IL-17A (secukinumab). Further clinical trials, including a humanized IgG4 specific for IL-17 (ixekizumab) and a fully human antibody that targets the IL-17 receptor A (brodalumab).
termedia.pl